Cargando…

Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion

Ovarian cancer (OC) is the second most common type of gynecological malignancy; it has poor survival rates and is frequently (>75%) diagnosed at an advanced stage. Platinum-based chemotherapy, with, e.g., carboplatin, is the standard of care for OC, but toxicity and acquired resistance to therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Koren Carmi, Yifat, Mahmoud, Hatem, Khamaisi, Hazem, Adawi, Rina, Gopas, Jacob, Mahajna, Jamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555577/
https://www.ncbi.nlm.nih.gov/pubmed/32906729
http://dx.doi.org/10.3390/ijms21186533
_version_ 1783594039981899776
author Koren Carmi, Yifat
Mahmoud, Hatem
Khamaisi, Hazem
Adawi, Rina
Gopas, Jacob
Mahajna, Jamal
author_facet Koren Carmi, Yifat
Mahmoud, Hatem
Khamaisi, Hazem
Adawi, Rina
Gopas, Jacob
Mahajna, Jamal
author_sort Koren Carmi, Yifat
collection PubMed
description Ovarian cancer (OC) is the second most common type of gynecological malignancy; it has poor survival rates and is frequently (>75%) diagnosed at an advanced stage. Platinum-based chemotherapy, with, e.g., carboplatin, is the standard of care for OC, but toxicity and acquired resistance to therapy have proven challenging. Despite advances in OC diagnosis and treatment, approximately 85% of patients will experience relapse, mainly due to chemoresistance. The latter is attributed to alterations in the cancer cells and is also mediated by tumor microenvironment (TME). Recently, we reported the synthesis of a platinum (IV) prodrug that exhibits equal potency toward platinum-sensitive and resistant OC cell lines. Here, we investigated the effect of TME on platinum sensitivity. Co-culture of OC cells with murine or human mesenchymal stem cells (MS-5 and HS-5, respectively) rendered them resistant to chemotherapeutic agents, including platinum, paclitaxel and colchicine. Platinum resistance was also conferred by co-culture with differentiated murine adipocyte progenitor cells. Exposure of OC cells to chemotherapeutic agents resulted in activation of phospho-ERK1/2. Co-culture with MS-5, which conferred drug resistance, was accompanied by blockage of phospho-ERK1/2 activation. The flavonoids fisetin and quercetin were active in restoring ERK phosphorylation, as well as sensitivity to platinum compounds. Exposure of OC cells to cobimetinib—a MEK1 inhibitor that also inhibits extracellular signal-regulated kinase (ERK) phosphorylation—which resulted in reduced sensitivity to the platinum compound. This suggests that ERK activity is involved in mediating the function of flavonoids in restoring platinum sensitivity to OC co-cultured with cellular components of the TME. Our data show the potential of combining flavonoids with standard therapy to restore drug sensitivity to OC cells and overcome TME-mediated platinum drug resistance.
format Online
Article
Text
id pubmed-7555577
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75555772020-10-19 Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion Koren Carmi, Yifat Mahmoud, Hatem Khamaisi, Hazem Adawi, Rina Gopas, Jacob Mahajna, Jamal Int J Mol Sci Article Ovarian cancer (OC) is the second most common type of gynecological malignancy; it has poor survival rates and is frequently (>75%) diagnosed at an advanced stage. Platinum-based chemotherapy, with, e.g., carboplatin, is the standard of care for OC, but toxicity and acquired resistance to therapy have proven challenging. Despite advances in OC diagnosis and treatment, approximately 85% of patients will experience relapse, mainly due to chemoresistance. The latter is attributed to alterations in the cancer cells and is also mediated by tumor microenvironment (TME). Recently, we reported the synthesis of a platinum (IV) prodrug that exhibits equal potency toward platinum-sensitive and resistant OC cell lines. Here, we investigated the effect of TME on platinum sensitivity. Co-culture of OC cells with murine or human mesenchymal stem cells (MS-5 and HS-5, respectively) rendered them resistant to chemotherapeutic agents, including platinum, paclitaxel and colchicine. Platinum resistance was also conferred by co-culture with differentiated murine adipocyte progenitor cells. Exposure of OC cells to chemotherapeutic agents resulted in activation of phospho-ERK1/2. Co-culture with MS-5, which conferred drug resistance, was accompanied by blockage of phospho-ERK1/2 activation. The flavonoids fisetin and quercetin were active in restoring ERK phosphorylation, as well as sensitivity to platinum compounds. Exposure of OC cells to cobimetinib—a MEK1 inhibitor that also inhibits extracellular signal-regulated kinase (ERK) phosphorylation—which resulted in reduced sensitivity to the platinum compound. This suggests that ERK activity is involved in mediating the function of flavonoids in restoring platinum sensitivity to OC co-cultured with cellular components of the TME. Our data show the potential of combining flavonoids with standard therapy to restore drug sensitivity to OC cells and overcome TME-mediated platinum drug resistance. MDPI 2020-09-07 /pmc/articles/PMC7555577/ /pubmed/32906729 http://dx.doi.org/10.3390/ijms21186533 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Koren Carmi, Yifat
Mahmoud, Hatem
Khamaisi, Hazem
Adawi, Rina
Gopas, Jacob
Mahajna, Jamal
Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion
title Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion
title_full Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion
title_fullStr Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion
title_full_unstemmed Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion
title_short Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion
title_sort flavonoids restore platinum drug sensitivity to ovarian carcinoma cells in a phospho-erk1/2-dependent fashion
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555577/
https://www.ncbi.nlm.nih.gov/pubmed/32906729
http://dx.doi.org/10.3390/ijms21186533
work_keys_str_mv AT korencarmiyifat flavonoidsrestoreplatinumdrugsensitivitytoovariancarcinomacellsinaphosphoerk12dependentfashion
AT mahmoudhatem flavonoidsrestoreplatinumdrugsensitivitytoovariancarcinomacellsinaphosphoerk12dependentfashion
AT khamaisihazem flavonoidsrestoreplatinumdrugsensitivitytoovariancarcinomacellsinaphosphoerk12dependentfashion
AT adawirina flavonoidsrestoreplatinumdrugsensitivitytoovariancarcinomacellsinaphosphoerk12dependentfashion
AT gopasjacob flavonoidsrestoreplatinumdrugsensitivitytoovariancarcinomacellsinaphosphoerk12dependentfashion
AT mahajnajamal flavonoidsrestoreplatinumdrugsensitivitytoovariancarcinomacellsinaphosphoerk12dependentfashion